Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis.
cam.depositDate | 2022-06-24 | |
cam.issuedOnline | 2022-05-14 | |
dc.contributor.author | Schwarz, Tatjana | |
dc.contributor.author | Otto, Carolin | |
dc.contributor.author | Jones, Terry C | |
dc.contributor.author | Pache, Florence | |
dc.contributor.author | Schindler, Patrick | |
dc.contributor.author | Niederschweiberer, Moritz | |
dc.contributor.author | Schmidt, Felix A | |
dc.contributor.author | Drosten, Christian | |
dc.contributor.author | Corman, Victor M | |
dc.contributor.author | Ruprecht, Klemens | |
dc.contributor.orcid | Jones, Terry C [0000-0003-1120-9531] | |
dc.contributor.orcid | Corman, Victor M [0000-0002-3605-0136] | |
dc.date.accessioned | 2022-06-24T23:31:04Z | |
dc.date.available | 2022-06-24T23:31:04Z | |
dc.date.issued | 2022-06 | |
dc.date.updated | 2022-06-24T10:10:13Z | |
dc.description.abstract | BACKGROUND: Optimal management of anti-CD20-treated patients with multiple sclerosis (pwMS) is an important clinical task during the current severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. OBJECTIVES: To characterize humoral and cellular immune responses to SARS-CoV-2 vaccinations/infections in a longitudinal cohort of anti-CD20 treated (n = 175) and anti-CD20 therapy-naïve (n = 41) pwMS. METHODS: Anti-SARS-CoV-2 spike protein immunoglobulin G (IgG) and IgA, virus neutralizing capacity, IgG avidity and SARS-CoV-2-specific T cells were determined. RESULTS: Following two SARS-CoV-2 vaccinations, not only SARS-CoV-2 spike protein IgG and IgA, but also neutralizing capacity and avidity of SARS-CoV-2 IgG were lower in anti-CD20-treated (n = 51) than in anti-CD20 therapy-naïve pwMS (n = 14) and in healthy controls (HC, n = 19). However, in all anti-CD20-treated pwMS vaccinated twice (n = 26) or infected with SARS-CoV-2 (n = 2), in whom SARS-CoV-2-specific T cells were measured, SARS-CoV-2-specific T cells were detectable, at levels similar to those of twice-vaccinated anti-CD20 therapy-naïve pwMS (n = 7) and HC (n = 19). SARS-CoV-2-S1 IgG levels (r = 0.42, p = 0.002), antibody avidity (r = 0.7, p < 0.001), and neutralizing capacity (r = 0.44, p = 0.03) increased with time between anti-CD20 infusion and second vaccination. Based on detection of SARS-CoV-2 antibodies, SARS-CoV-2 infections occurred in 4 out of 175 (2.3%) anti-CD20-treated pwMS, all of whom recovered fully. CONCLUSIONS: These findings should inform treatment decisions and SARS-CoV-2 vaccination management in pwMS. | |
dc.format.medium | Print-Electronic | |
dc.identifier.doi | 10.17863/CAM.85774 | |
dc.identifier.eissn | 1477-0970 | |
dc.identifier.issn | 1352-4585 | |
dc.identifier.uri | https://www.repository.cam.ac.uk/handle/1810/338365 | |
dc.language.iso | eng | |
dc.publisher | SAGE Publications | |
dc.publisher.url | http://dx.doi.org/10.1177/13524585221094478 | |
dc.rights | Attribution-NonCommercial 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | |
dc.subject | Multiple sclerosis | |
dc.subject | SARS-CoV-2 | |
dc.subject | T cells | |
dc.subject | anti-CD20 therapy | |
dc.subject | antibodies | |
dc.subject | vaccination | |
dc.subject | Antibodies, Viral | |
dc.subject | COVID-19 | |
dc.subject | COVID-19 Vaccines | |
dc.subject | Humans | |
dc.subject | Immunoglobulin A | |
dc.subject | Immunoglobulin G | |
dc.subject | Multiple Sclerosis | |
dc.subject | SARS-CoV-2 | |
dc.subject | Spike Glycoprotein, Coronavirus | |
dc.subject | T-Lymphocytes | |
dc.subject | Vaccination | |
dc.title | Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis. | |
dc.type | Article | |
dcterms.dateAccepted | 2022-03-29 | |
prism.endingPage | 1050 | |
prism.issueIdentifier | 7 | |
prism.number | ARTN 13524585221094478 | |
prism.publicationDate | 2022 | |
prism.publicationName | Mult Scler | |
prism.startingPage | 1041 | |
prism.volume | 28 | |
pubs.licence-display-name | Apollo Repository Deposit Licence Agreement | |
pubs.licence-identifier | apollo-deposit-licence-2-1 | |
rioxxterms.type | Journal Article/Review | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1177/13524585221094478 |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis.pdf
- Size:
- 1.7 MB
- Format:
- Adobe Portable Document Format
- Description:
- Published version
- Licence
- https://creativecommons.org/licenses/by-nc/4.0/